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Cardiac Imaging
High-Dose Adenosine Overcomes the Attenuation
of Myocardial Perfusion Reserve Caused by Caffeine
Eliana Reyes, MD,*† Chee Y. Loong, MRCP,*† Mark Harbinson, MD, MRCP,†
Jackie Donovan, MSC, DIPRCPATH,‡ Constantinos Anagnostopoulos, MD, PHD, FRCP, FRCR, FESC,†
S. Richard Underwood, MD, FRCP, FRCR, FESC, FACC*†
London, United Kingdom
Objectives We studied whether an increase in adenosine dose overcomes caffeine antagonism on adenosine-mediated cor-
onary vasodilation.
Background Caffeine is a competitive antagonist at the adenosine receptors, but it is unclear whether caffeine in coffee al-
ters the actions of exogenous adenosine, and whether the antagonism can be surmounted by increasing the
adenosine dose.
Methods Myocardial perfusion scintigraphy (MPS) was used to assess adenosine-induced hyperemia in 30 patients before
(baseline) and after coffee ingestion (caffeine). At baseline, patients received 140 g/kg/min of adenosine com-
bined with low-level exercise. For the caffeine study, 12 patients received 140 g/kg/min of adenosine (stan-
dard) and 18 patients received 210 g/kg/min (high dose) after caffeine intake (200 mg). Myocardial perfusion
was assessed semiquantitatively and quantitatively, and perfusion defect was characterized according to the
presence of reversibility.
Results Caffeine reduced the magnitude of perfusion abnormality induced by standard adenosine as measured by the
summed difference score (SDS) (12.0  4.4 at baseline vs. 4.1  2.1 after caffeine, p  0.001) as well as de-
fect size (18% [3% to 38%] vs. 8% [0% to 22%], p  0.01), whereas it had no effect on the abnormalities
caused by high-dose adenosine (SDS, 7.7  4.0 at baseline vs. 7.8  4.2 after caffeine, p  0.7). There was
good agreement between baseline and caffeine studies for segmental defect category (kappa  0.72, 95% con-
fidence interval: 0.65 to 0.79) in the high-dose group. An increase in adenosine after caffeine intake was well
tolerated.
Conclusions Caffeine in coffee attenuates adenosine-induced coronary hyperemia and, consequently, the detection of perfu-
sion abnormality by adenosine MPS. This can be overcome by increasing the adenosine dose without compro-
mising test tolerability. (J Am Coll Cardiol 2008;52:2008–16) © 2008 by the American College of Cardiology
Foundation
Adenosine is a potent coronary vasodilator that increases
myocardial blood flow up to 4-fold and provokes flow
heterogeneity and even ischemia in territories served by
stenosed epicardial coronary arteries (1). According to
experimental data (2,3), methylxanthines can attenuate the
coronary hyperemic response to adenosine through the
blockade of arteriolar A2A adenosine receptors, thereby
potentially halting the detection of flow-limiting coronary
artery disease (CAD) by adenosine myocardial perfusion
scintigraphy (MPS). A limited body of evidence indicates
that caffeine, a 1,3,7-trimethylxanthine that binds to the
ubiquitous adenosine receptors in a competitive manner (4),
can abolish myocardial blood flow heterogeneity induced by
dipyridamole, a vasodilator agent that acts by augmenting
the concentration of endogenous adenosine (5,6). On this
basis, it might be expected that caffeine would also inhibit
hyperemia by exogenous adenosine. However, recent studies
have shown that caffeine does not modify the coronary
vasodilator response to adenosine and have suggested that at
the doses given, adenosine results in greater concentrations
of adenosine molecules than dipyridamole to compete with
caffeine for receptor occupancy (7,8). Other factors such as
variations in study methodology, subject population, and
caffeine dose could also account for these discrepant results.
The effect of caffeine on adenosine MPS remains unclear.
Furthermore, adenosine stress testing is increasingly per-
formed with supplemental exercise yet the effect of caffeine on
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this modality of stress is unknown. Because of the competitive
interaction between adenosine and caffeine, receptor block-
ade by caffeine could be surmounted by increasing the
adenosine dose; however, the effectiveness of this measure
has not been examined. Thus, we hypothesized that caffeine
in coffee would reduce the magnitude of the reversibility of
a perfusion abnormality demonstrated by adenosine MPS,
and that an increase in adenosine would overcome caffeine
antagonism and provoke the same perfusion abnormality in
the presence of caffeine compared with the abnormality
using a standard protocol after caffeine abstention.
Methods
Study design and subject selection. This was a prospec-
tive single-center study. Patients were eligible if they had
suspected or known CAD (i.e., previous myocardial infarc-
tion, revascularization, or documented angiographically sig-
nificant coronary artery stenosis) and were scheduled for
adenosine MPS (baseline procedure) for the clinical assess-
ment of anginal symptoms. Patients were enrolled if they
had refrained from caffeine-containing products for at least
12 h before stress testing and had unequivocal reversible
myocardial perfusion abnormality at baseline. Patients who
fulfilled the entry criteria returned for repeat adenosine
MPS after caffeine intake. Exclusion criteria were as follows:
1) contraindication to adenosine, intolerable symptoms, or
adverse reaction during baseline procedure; 2) left bundle
branch block or paced rhythm on resting electrocardiogram;
3) serum caffeine concentration 2 mg/l at baseline;
4) reversibility involving 10% of total left ventricular
myocardium or, in other words, 2 of 17 myocardial
segments on baseline MPS; and 5) change in symptoms,
medication, or documented acute ischemic event or coro-
nary intervention between the 2 MPS procedures. A total of
30 patients were enrolled in the study. The Royal Brompton
and Harefield Research Ethics Committee approved the
study, and written informed consent was obtained from all
patients.
Study protocol. All patients made 2 visits. For each visit,
patients were asked to refrain from caffeinated products for
a minimum of 12 h before the test. Medications were not
altered. For the baseline procedure (visit 1), stress testing
was performed with adenosine infused at the standard dose
of 140 g/kg/min for 6 min combined with low-level
exercise on a bicycle ergometer. Patients unable to cycle
performed isometric exercise with handgrip. A blood sample
was drawn immediately before the start of the adenosine
infusion to measure caffeine concentration. Within 6 weeks
of the baseline procedure (visit 2), repeat stress testing was
performed 60 min after ingestion of coffee to allow plasma
caffeine level to reach its maximum (9). To determine the
effect of caffeine on adenosine MPS, 12 patients received
adenosine at 140 g/kg/min for 6 min combined with
exercise as for the baseline study (standard adenosine
group). To demonstrate the efficacy of high-dose adenosine,
18 patients received 210 g/kg/
min of adenosine for 6 min with
supplemental exercise performed
in identical way as baseline
(high-dose adenosine group). As
for the baseline study, blood was
drawn before the start of the
adenosine infusion to measure
caffeine concentration.
The electrocardiographic rhythm
was monitored throughout each
stress procedure, and blood pres-
sure and heart rate recorded ev-
ery 2 min. Symptoms were re-
corded as reported by the patient,
who was also questioned directly about symptoms every 2
min until completion of the test. Patient symptoms were
graded at the time of test using a symptom-severity score
from 0 (none) to 3 (severe). A summed score was obtained
by addition of the score for each symptom. Safety was
assessed by collection of vital signs, electrocardiographic
data, and adverse events during each procedure. Detailed
information on daily caffeine consumption, smoking habit,
medications, and co-morbidities including history of he-
patic or renal disease was collected by a questionnaire.
Dietary caffeine intake was estimated according to previ-
ously published data (10,11).
Caffeine administration. Coffee was prepared on-site us-
ing a 15-bar pump pressure espresso machine. Patients were
given 2 large shots of espresso, which, according to previous
reports, would provide 200 mg of caffeine (10), the total
caffeine content in 2 standard cups of coffee or in a 355-ml
(12-fl oz) serving of brewed coffee from specialty shops (10).
The dosage was chosen to reach a serum caffeine concen-
tration 2 mg/l, which is known to inhibit the hemody-
namic response to intravenous adenosine (12).
Serum caffeine. Blood samples were taken from a vein
cannula, and total serum concentration of caffeine (protein
bound and unbound) was measured by a commercially
available homogenous enzyme immunoassay technique
(Emit Assay, Dade Behring Ltd., Milton Keynes, United
Kingdom).
Image processing. For the baseline procedure, 80 to 120
MBq (2.2 to 3.2 mCi) of thallium-201 was injected 3 min
into the adenosine infusion and stress image acquisition
started within 10 min of thallium-201 injection. Rest
images were acquired 3 to 4 h later after an additional
injection of 40 MBq (1.1 mCi) of thallium-201. For the
repeat MPS procedure, stress images were acquired in an
identical way as for baseline. Rest imaging was not con-
ducted to minimize radiation exposure to the patient.
Emission tomographic imaging was performed using a
dual-headed gamma camera (Optima, IGE Medical Sys-
tems, Milwaukee, Wisconsin) equipped with a low-energy
all-purpose collimator. Patients were supine, and 64 projec-
tions were acquired over a semicircular 180° arc from 45°
Abbreviations
and Acronyms
CAD  coronary artery
disease
MI  myocardial infarction
MPS  myocardial
perfusion scintigraphy
SDS  summed difference
score
SSS  summed stress
score
TID  transient ischemic
dilation
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right anterior oblique to 45° left posterior oblique. A 20%
symmetrical energy window was used at 72 and 167 keV.
Transverse tomograms of the left ventricle were recon-
structed using a Hanning pre-filter with a cutoff frequency
of 0.75 cycles/cm and a ramp filter during back-projection.
Transaxial slices were reoriented according to current rec-
ommendations (13). No attenuation correction was applied.
Image interpretation. Unprocessed planar images were
displayed in the cine format to assess quality and to exclude
significant patient motion or attenuation. The tomographic
slices were divided into 17 segments, and tracer uptake was
graded semiquantitatively for each segment by 2 experi-
enced nuclear cardiologists without knowledge of clinical
data or caffeine status. In case of disagreement, the segment
was assigned to a category by a third reader. Scores were
attributed on a 5-point system by taking into account the
severity of the perfusion defect: 0  normal uptake (tracer
activity 70% of maximal myocardial activity); 1  mild
reduction (50% to 69%); 2  moderate reduction (30% to
49%); 3  severe reduction (10% to 29%); and 4  absent
uptake (tracer activity 0% to 9% of maximum). For each
patient, the summed stress score (SSS) and summed rest
score (SRS) were obtained by addition of the perfusion score
for each segment. The summed difference score (SDS) was
estimated by subtracting the SSS from the SRS, and this
measure was used to define the extent and depth of
reversibility.
Each myocardial segment was classified further as show-
ing a fixed, reversible, or partially reversible (mixed) defect,
or as normal. Segments were also assigned to 1 of the
following territories: left anterior descending artery (seg-
ments 1, 2, 7, 8, 13, 14, and 17), left circumflex artery
(segments 5, 6, 11, 12, and 16), and right coronary artery
(segments 3, 4, 9, 10, and 15) (13). Each territory was
characterized using the same segmental classification. De-
fect size was quantified as a percentage of the myocardium
involved in the left anterior descending, left circumflex, or
right coronary artery territory. Quantitative defect size,
transient ischemic dilation (TID [stress/rest left ventricular
volumes ratio 1.22]) and lung thallium-201 uptake (lung/
heart counts ratio 0.45) were calculated using a commer-
cially available program (Quantitative Perfusion SPECT
[single-positron emission computed tomography], Cedars-
Sinai Medical Center, Los Angeles, California).
Statistical analysis. Results were summarized as mean ( SD)
or median (interquartile range). Histogram plots and the
Shapiro-Wilk W test were used to test for normality. When
this was the case, comparisons within the groups were
performed using the t test for paired observations. Non-
normally distributed data were analyzed using the Wilcoxon
signed-rank test. Comparison between groups was performed
with the 2-sample t test. Categorical differences were examined
with the chi-square test or with the McNemar test for paired
observations. Pearson correlation was used to assess the
variation in SDS according to serum caffeine concentration.
The primary outcome measures were SDS and segmental
defect classification at baseline and after caffeine intake. A
reduction in baseline SDS of at least 40% after caffeine was
considered to be clinically relevant. A sample of 12 patients
gives 90% power to detect such difference (2-sided signifi-
cance at alpha  0.05). Agreement for segmental defect
classification between baseline and caffeine studies was
examined to determine whether high-dose adenosine would
provoke the same defect in the presence of caffeine com-
pared with the defect at baseline. Because agreement is
likely to be better than that expected by chance, the value in
the null hypothesis was set at 0.40. A total of 308 myocar-
dial segments gives 90% power to detect a kappa value of
0.70 (2-sided significance at alpha  0.05), which is
indicative of good agreement (14). Differences were consid-
ered statistically significant at p values 0.05 (2-sided).
Analysis was performed using SPSS version 14.0 (SPSS
Inc., Chicago, Illinois).
Results
Patient characteristics. Patient characteristics are summa-
rized in Table 1. Both adenosine MPS procedures were
completed at a median interval of 12 days (range 6 to 21
days). All patients were habitual caffeine consumers with a
median daily consumption of 5 cups (range 1 to 10 cups) of
tea or coffee, or both, which represents a median caffeine
intake of 300 mg/day (range 60 to 600 mg/day). None of
the patients had a history of hepatic or renal impairment.
Serum caffeine concentration. At baseline, caffeine was
undetectable in 17 patients (serum caffeine concentration
0.1 mg/l) and ranged from 0.2 to 1.3 mg/l in 13 patients
after abstention from caffeinated products for a median 18 h
(range 12 to 41 h) (Table 2). Sixty minutes after ingestion
of coffee, serum caffeine concentration increased signifi-
cantly (Fig. 1).
Baseline. At baseline, adenosine stress provoked a sig-
nificant increase in heart rate and rate pressure product in
both the standard and high-dose adenosine groups,
whereas there was no change in systolic or diastolic blood
pressure (Table 3). There was no difference between
groups for any of the hemodynamic measures (p  0.05
for all comparisons).
Caffeine. Resting heart rate, blood pressure, and rate pressure
product did not change significantly after caffeine intake (Table
3). Similarly, caffeine had no effect on the hemodynamic
response to either standard or high-dose adenosine. No
statistically significant difference was found between
groups for any of the hemodynamic parameters (p  0.05
for all comparisons).
Effect of Caffeine on Adenosine MPS
Standard adenosine. Mean SDS decreased by 65% (95%
CI: 58% to 73%) after caffeine intake (12.0 4.4 at baseline
vs. 4.1  2.1 after caffeine, p  0.001). Individual SDS is
shown in Figure 2. The mean difference in SSS and SDS
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between baseline and caffeine studies was 7.9  3.0 and
7.8  3.2, respectively (Fig. 3). Representative images are
shown in Figure 4.
The number of fully or partially reversible myocardial
segments detected per patient decreased significantly from
7.1 1.8 at baseline to 3.7 1.6 after caffeine intake (mean
difference: 3.4, 95% CI: 2.4 to 4.5, p  0.001). In addition,
quantitative analysis showed a significant reduction in the
median size of perfusion defect from 18% (3% to 38%) at
baseline to 8% (0% to 22%) after caffeine (p  0.01), with
9 patients demonstrating a multivessel disease distribution
at baseline compared with 2 patients after caffeine intake
(p  0.02).
No statistically significant relationship was found be-
tween SDS changes from baseline to the caffeine study and
serum caffeine concentration (r  0.26, p  0.4). With
regard to nonperfusion markers of ischemia, TID was
observed in 2 patients and increased thallium-201 lung
uptake in 1 patient at baseline but not after coffee ingestion
(Fig. 4).
High-dose adenosine. In contrast to the standard adeno-
sine group, mean SDS did not change significantly after
caffeine intake in the high-dose group (7.7 4.0 at baseline
vs. 7.8  4.2 after caffeine, p  0.7) (Fig. 2). The mean
difference in SSS and SDS between baseline and caffeine
studies was 0.2 2.3 and 0.1 2.4, respectively, which was
significantly smaller than the mean difference in SSS and
SDS observed with standard adenosine (p  0.001 in both
cases) (Fig. 3).
There was no significant difference in the number of
abnormal myocardial segments detected per patient at
baseline and after caffeine intake (6.8  2.9 vs. 6.7  2.5,
p  0.8). The number of fully or partially reversible
segments was also similar (6.0  2.4 at baseline vs. 5.4 
2.2 after caffeine, p  0.6). On a segmental basis, overall
agreement for defect category between baseline and caffeine
Patient Characteristics by Stress Protocol
Table 1 Patient Characteristics by Stress Protocol
All Patients
Standard
Adenosine
High-Dose
Adenosine p Value
n 30 12 18 —
Age, yrs 65 7 66 6 64 7 0.4
Weight, kg 82 23 83 32 81 14 0.8
Body mass index, kg/m2 28 3 29 4 27 3 0.1
Hypertension, n (%) 15 (50) 8 (67) 7 (39) 0.1
Hypercholesterolemia, n (%) 20 (67) 7 (58) 13 (72) 0.4
Smoking, n (%) 12 (40) 4 (33) 8 (44) 0.7
Diabetes mellitus, n (%) 10 (33) 6 (50) 4 (22) 0.1
Symptoms, n (%)
Chest pain 25 (83) 10 (83) 15 (83) 0.9
Exertional dyspnea 21 (70) 10 (83) 11 (61) 0.2
Known CAD, n (%) 24 (80) 9 (75) 15 (83) 0.5
Previous MI, n (%) 14 (47) 4 (33) 10 (56) 0.2
Previous revascularization, n (%)
PCI 10 (33) 5 (42) 5 (28) 0.4
CABG 10 (33) 3 (25) 7 (39) 0.4
Medication, n (%)
Beta-blocker 20 (67) 7 (58) 13 (72) 0.4
Calcium antagonist 8 (27) 3 (25) 5 (28) 0.8
Nitrates 6 (20) 3 (25) 3 (17) 0.5
Nicorandil 9 (30) 4 (33) 5 (28) 0.7
Aspirin 24 (80) 10 (83) 14 (78) 0.7
Statin 19 (63) 7 (58) 12 (67) 0.6
Values are mean  SD where appropriate.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Serum Caffeine Concentration
Table 2 Serum Caffeine Concentration
Standard Adenosine
(n  12)
High-Dose Adenosine
(n  18) p Value
Baseline, mg/l 0.2 0.3 (0.0 to 0.8) 0.3 0.4 (0.0 to 1.3) 0.2
Caffeine, mg/l 6.2 2.6 (3.9 to 12.3)* 5.7 2.0 (2.9 to 9.6)* 0.5
Difference between caffeine
and baseline, mg/l
5.9 2.7 (3.2 to12.3) 5.4 2.1 (2.0 to9.3) 0.3
Data presented as mean  SD (range). *p  0.01 versus baseline.
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studies was 84% (258 of 306 segments, kappa  0.72, 95%
CI: 0.65 to 0.79) (Table 4). On a vascular territory basis,
agreement for defect category was 87% (47 of 54 territories,
kappa  0.81, 95% CI: 0.69 to 0.93). Regarding nonper-
fusion markers of ischemia, TID was present in 2 patients
both at baseline and after caffeine intake. A case example is
shown in Figure 5.
Side effects. At baseline, 26 of 30 (87%) patients experi-
enced side effects during adenosine stress testing (Table 5).
Of 47 side effects, 44 (94%) were graded as mild. None of
the side effects was graded as severe. After caffeine intake,
the total occurrence of side effects decreased by 71% in the
standard adenosine group. The summed symptom score also
decreased from 1.6  1.1 at baseline to 0.6  0.7 after
caffeine (p  0.02). In contrast, the frequency of side effects
at baseline and after caffeine was similar in the high-dose
group (Table 5). The summed symptom score was also
similar (1.4  1.1 at baseline vs. 1.3  1.2 after caffeine,
p  0.9). There were no electrocardiographic changes
attributable to either caffeine intake or a high dose of
adenosine. No adverse events occurred, and no patient
needed aminophylline, dose reduction, or early termination
of the adenosine infusion either at baseline or after caffeine.
Discussion
The present study is the first to demonstrate that caffeine in
coffee attenuates the magnitude of myocardial perfusion
abnormality elicited by adenosine stress testing. According
to the study, intake of caffeine before stress may result in
significant underestimation of the extent of flow-limiting
coronary disease by adenosine MPS, which has important
implications for patient management. This observation
strengthens the hypothesis that caffeine is an effective
antagonist at the coronary adenosine receptors. The study
also shows for the first time that the inhibitory effect of
caffeine on adenosine-induced hyperemia can be sur-
mounted by increasing the adenosine dose. These results all
together provide further evidence of the competitive inter-
action between adenosine and caffeine and its potential
impact on the efficacy of vasodilator stress.
Caffeine is the most widely consumed psychoactive drug,
with a per capita consumption estimated at 280 mg/day in
the U.S. and as high as 400 mg/day in the Scandinavian
countries and in the United Kingdom (15). Coffee is the
main source of caffeine worldwide. Caffeine content in a
regular cup of coffee varies greatly depending on the variety
of coffee bean and brewing method used (10,16), and thus
caution must be exercised when relating the physiological
effects of caffeine to coffee intake rather than to actual
caffeine concentrations. In addition, caffeine levels in plasma
after coffee ingestion can vary widely owing to interindi-
vidual differences in caffeine metabolism (9,17), which is the
Figure 1 Serum Caffeine After Coffee Ingestion
Distribution of serum caffeine concentrations across
the study population after coffee consumption (n  30).
Hemodynamic Response to Adenosine Stress
Table 3 Hemodynamic Response to Adenosine Stress
Standard Adenosine (n  12) High-Dose Adenosine (n  18)
Baseline
140 g/kg/min*
Caffeine
140 g/kg/min
Baseline
140 g/kg/min
Caffeine
210 g/kg/min
Rest
HR, beats/min 65 12 65 13 63 9 65 10
SBP, mm Hg 146 18 141 16 143 18 144 19
DBP, mm Hg 83 10 86 8 83 12 84 11
RPP, 103 mm Hg · min1 9.5 1.9 9.2 2.0 9.1 1.9 9.3 2.2
Stress
HR, beats/min 91 17† 88 17† 94 14† 97 12†
SBP, mm Hg 152 20 152 16 149 18 143 20
DBP, mm Hg 83 11 87 12 82 14 79 11
RPP, 103 mm Hg · min1 13.8 3.2† 13.3 2.5† 14.0 2.5† 13.8 2.7†
Peak watts, median (range)‡ 75 (15 to 75) 75 (15 to 75) 75 (25 to 75) 75 (25 to 75)
Values are mean  SD unless indicated otherwise. *Adenosine dose. †p  0.01 versus rest values. ‡Patients unable to cycle (n  2) performed
isometric exercise with handgrip.
DBP  diastolic blood pressure; HR  heart rate; RPP  rate-pressure product; SBP  systolic blood pressure.
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most likely explanation for the observed variability in serum
caffeine concentrations despite standard brewing of the
same coffee brand.
In line with recent observations (18), coffee ingestion had
no effect on resting blood pressure or heart rate, probably
because of caffeine habituation and development of toler-
ance (19). As indicated in previous experimental studies
(20,21), our results suggest that caffeine habituation does not
modify the potency of caffeine at the adenosine receptors.
The primary mechanism of action of caffeine in humans
occurs through the blockade of adenosine receptors (2,22).
Although caffeine interacts with the receptors at low con-
centrations (2,3), it is relatively less potent than other
xanthines at the A2A subtype, which is responsible for the
coronary vasodilator effect of adenosine (2). Indeed, caffeine
had no effect on myocardial blood flow heterogeneity
induced by intravenous adenosine at plasma concentrations
that were almost one-half the concentrations attained in the
present study (7). Similar concentrations of caffeine did not
modify the hyperemic response to intracoronary adenosine
as measured by the fractional flow reserve in patients with
angiographically significant coronary artery stenosis (8).
Also, comparable caffeine levels do not appear to attenuate
the peak hyperemic effect of selective A2A adenosine recep-
tor agonism (23).
By contrast, administration of a high dose of caffeine was
effective at inhibiting selective A2A-receptor–mediated cor-
onary vasodilation in a canine model (24). The results of the
present study extend this observation to the clinical setting
and support the notion that at a dose commonly encoun-
tered in daily life, caffeine blocks the coronary A2A receptors
from adenosine, thereby attenuating its vasodilator action
and potentially reducing the sensitivity of adenosine MPS
for the detection of coronary stenosis. Caffeine also reduced
Figure 2 SDS at Baseline and After Caffeine
Individual and mean (95% confidence interval) summed difference score (SDS) at baseline and
after caffeine intake during (A) standard and (B) high-dose adenosine myocardial perfusion scintigraphy.
Figure 3 Mean Difference in SSS and SDS Between Baseline and Caffeine Studies
Mean difference in (A) summed stress scores (SSS) and (B) summed difference scores (SDS) between baseline and
caffeine myocardial perfusion scintigraphy studies for the standard and high-dose adenosine groups. Error bars represent  SEM.
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the frequency and severity of adenosine-related side effects,
reflecting its nonselective action at the various adenosine
receptors (2,3). The lack of a concentration-response effect
of serum caffeine levels on the reversibility of perfusion
abnormality in the present study was most likely the result
of insufficient statistical power to detect such an effect.
The current study also demonstrates that, in the presence
of inhibitory concentrations of caffeine, administration of
210 g/kg/min of adenosine elicits myocardial perfusion
abnormality similar to that of unantagonized adenosine.
This finding indicates that an increase in dose restores
coronary responsiveness to adenosine and that, in most
instances, a 50% increment would be sufficient to surmount
the inhibitory effect of a relatively large intake of caffeine.
Importantly, the use of a high dose of adenosine after coffee
ingestion was well tolerated regardless of serum caffeine
concentration.
It is not possible to determine from this study whether
the observed changes of inducible perfusion abnormality are
due to reduction of hyperemic perfusion or to increase in
baseline perfusion. However, previous positron emission
tomography studies have shown that caffeine does not
increase resting perfusion (6,18); therefore, we can assume
that caffeine-induced changes are due to a reduction in
adenosine-induced hyperemia.
Finally, the study highlights the difficulties in standardizing
the use of adenosine in patients who have consumed caffeine,
and underscores the importance of screening for caffeine intake
before adenosine MPS. According to our results, patients who
consume caffeine within a few hours before the test could be
considered for high-dose adenosine stress testing.
Figure 4 MPS Images of Same Patient Illustrating Effect of Caffeine on Standard Adenosine MPS
The baseline myocardial perfusion scintigraphy (MPS) images of a patient with a history of angina show extensive and profound apical and anteroseptal inducible perfu-
sion abnormalities associated with transient ischemic dilation and increased right ventricular thallium-201 uptake in the stress tomograms. After coffee (serum caffeine  12.3
mg/l), there is marked reduction in the magnitude of perfusion abnormalities. TID and abnormal right ventricular uptake are no longer present. HLA  horizontal long-axis view;
SA  short-axis view; VLA  vertical long-axis view.
Segmental Agreement Between Baseline and Caffeinetudies in the High-Dose Ad nosine Group Accordingto Type of Perfusion Abnormality (n  18)
Table 4
Segmental Agreement Between Baseline and Caffeine
Studies in the High-Dose Adenosine Group According
to Type of Perfusion Abnormality (n  18)
Caffeine, n (%)
Baseline, n (%) Normal Reversible Mixed Fixed
Normal 168 (55) 15 (5) 1 (0) 0 (0)
Reversible 19 (6) 55 (18) 0 (0) 3 (1)
Mixed 0 (0) 1 (0) 20 (7) 4 (1)
Fixed 0 (0) 0 (0) 5 (2) 15 (5)
Observed overall agreement 84% (258 of 306 segments).
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Study limitations. A potential limitation of the study is
that the effect of caffeine on standard and high-dose
adenosine was investigated in 2 separate groups of patients.
Ideally, patients should have undergone both interventions
but that would have resulted in an unacceptably high
radiation burden on the patient.
Detailed angiographic data were not available for all
patients, and therefore it was not possible to assess the
Figure 5 High-Dose Adenosine MPS After Caffeine in a Patient With Prior Myocardial Infarction and Recurrent Symptoms
The baseline myocardial perfusion scintigraphy (MPS) images show profound apical anteroseptal and mild inferoapical and inferoseptal inducible perfusion
abnormalities. After coffee ingestion (serum caffeine  8.9 mg/l) and high-dose adenosine (210 g/kg/min), the images are unchanged. Abbreviations as in Figure 4.
Side Effects During Adenosine Stress
Table 5 Side Effects During Adenosine Stress
Standard Adenosine (n  12) High-Dose Adenosine (n  18)
Side Effects
Baseline
140 g/kg/min*
Caffeine
140 g/kg/min
Baseline
140 g/kg/min
Caffeine
210 g/kg/min
Any symptom 10 (83) 5 (42)‡ 16 (89) 12 (67)
Chest pain 8 (67) 2 (17)§ 8 (44) 7 (39)
Dyspnea 6 (50) 4 (33) 7 (39) 8 (44)
Flushing 5 (42) 0 8 (44) 8 (44)
Headache 1 (8) 0 1 (6) 0
Dizziness 1 (8) 0 0 0
Abdominal discomfort 0 0 0 1 (6)
Other 1 (8) 0 1 (6) 1 (6)
Atrioventricular block 0 0 1 (6) 1 (6)
Ischemic ECG changes† 0 0 1 (6) 1 (6)
Data presented as n (%). *Adenosine infusion rate. †Horizontal or downsloping ST-segment depression0.1 mV 80 ms after the J point. ‡p 0.06
versus baseline. §p  0.05 versus baseline.
ECG  electrocardiogram.
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impact of caffeine intake on the diagnostic accuracy of
adenosine MPS. Nonetheless, our results strongly suggest
that moderate coffee ingestion before stress testing would
significantly reduce the sensitivity of adenosine MPS for the
detection of coronary stenosis.
We studied the effect of caffeine on adenosine combined
with exercise rather than on adenosine only. The fact that
adenosine stress testing is increasingly performed with
exercise is important, because results of studies on adenosine
only may not be easily extrapolated to the combined
protocol. The addition of exercise could have influenced the
results, although the paired design minimizes the potential
confounding effect. Exercise might have blunted the periph-
eral effects of caffeine and adenosine, but it is unlikely that
it would have potentiated caffeine antagonism. If anything,
exercise might partly have offset the antagonism in some
patients by eliciting active hyperemia.
Only males were recruited, and therefore our results may
not be transferable to females. In women, ovarian hormones
and their synthetic analogues can influence the metabolism
and gastrointestinal absorption of caffeine, thus potentially
altering both peak and time to peak levels of caffeine in
plasma (25). This potential confounding factor warrants
further investigation in female populations.
Conclusions
The present study demonstrates the competitive antagonism
between adenosine and caffeine, and the impact of such
interaction on myocardial perfusion imaging. Because of the
relatively low affinity of adenosine receptors for caffeine, the
effect of this xanthine is highly dose dependent. Moderate
coffee intake attenuates adenosine-induced vasodilation in a
surmountable manner, and thus an increase in adenosine
dose may represent an alternative approach to the manage-
ment of patients who consume caffeine before adenosine
stress testing. The potential benefit of such an intervention
provides a rationale to further investigate its feasibility and
safety in routine clinical practice.
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